Skip to main content
Caplight Logo









Eximis Surgical

Eximis Surgical

Private
Louisville, ColoradoHealthcare & Life Scienceshttps://www.eximissurgical.com/

Last Round

Series B

Apr 24, 2023

Total Funding Raised

$50.72M

Company Overview

Eximis Surgical is a medical device company that develops a proprietary surgical platform for the removal of large specimens through small incisions during minimally invasive surgeries.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

minimally invasive surgerylaparoscopic surgerysurgical specimen removalspecimen containmentmedical deviceMISlaparoscopic specimen bagsurgical segmentationlaparoscopic morcellationgynecologic oncologyintra-abdominal surgerysurgical techmedtechsurgical innovation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eximis Surgical Comparables

Compare Eximis Surgical with similar companies based on industry and business-model similarity.

Eximis Surgical comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Advanced Surgical Concepts
82%
Applied Medical
78%
Olympus Corporation
77%

Eximis Surgical Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BApr 24, 2023
Series BMar 21, 2023
Series AFeb 28, 2020
GrantMay 16, 2019
VC RoundNov 8, 2018
Series A
Mar 2, 2018

Eximis Surgical Investors

Notable investors and investment history

Eximis Surgical investors
InvestorRounds
Olympus Innovation VenturesSeries B
MedTech InnovatorSeed, Grant
Questa CapitalSeries A, VC Round, Series B
Venture Investors LLCSeries A, VC Round
Innosphere VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2023

    $9M round led by Questa Capital

  • May 16, 2019

    $250K grant round completed.

Eximis Surgical Filings

Explore SEC and related filing metadata, where available.

Eximis Surgical filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Eximis Surgical's valuation, stock price, and market status.

Is Eximis Surgical a public or private company?

Eximis Surgical is a private company.

What is the current stock price of Eximis Surgical?

Eximis Surgical is a private company with no public stock price. No recent secondary market data is available.

How much is Eximis Surgical worth (valuation)?

Valuation information for Eximis Surgical is not publicly available.

Can I buy Eximis Surgical stock?

Eximis Surgical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Eximis Surgical's last funding round?

Eximis Surgical's most recent funding round was Series B on March 21, 2023.

Who are the main investors in Eximis Surgical?

Key investors in Eximis Surgical include Questa Capital.

Will Eximis Surgical IPO soon?

No public IPO plans have been announced for Eximis Surgical.

How can I track Eximis Surgical secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Eximis Surgical's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLouisville, Colorado
Employee Range12
Year Founded2014
Last FundingApr 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?